Table 3

Duration and outcomes of LEN/PEM combination therapy

PatientDuration of LEN/PEM therapyPFSStatus at time of last follow-up*Patient on treatment at time of data cut-off
122 months19 monthsAWDYes
210 months6 monthsAWDYes
32 months2 monthsAWDNo
410 months5 monthsAWDYes
58 months8 monthsAWDYes
63 months2 monthsDODNo
73 months3 monthsDODNo
89 months9 monthsAWDYes
  • *Date of data cut-off: December 31, 2019.

  • AWD, alive with disease; DOD, died of disease; LEN, lenvatinib; PEM, pembrolizumab; PFS, progression-free survival.